Wave Life Sciences: Takeda Walks Away From Wave Huntington's Partnership After Sinking $260M in Collaboration

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on Wave's WVE-003 clinical-stage Huntington's disease program-a potential $5 billion commercial opportunity, according to the biotech.